Drug Trial Radar · NCT07201558
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Dec 2, 2025
Primary completion
Jun 27, 2028
Study completion Jun 27, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.
Conditions
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
Interventions
SurovatamigBiological
Surovatamig is a bispecific T-cell engager administered subcutaneously. This is an open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Surovatamig in adult participants with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study consists of up to three parts: Part 1 (SAD): Single ascending dose - participants receive one dose of Surovatamig. Part 2 (sSUD): Single step-up dosing - participants receive two doses. Part 3 (dSUD): Double step-up dosing - participants receive three doses. Participants are assigned to a study part based on protocol-defined criteria. The study includes follow-up for a minimum of 179 days post-first dose, with extended monitoring up to 12 months for certain participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs)Time frame: Day 1 to end of the study (up to 52 weeks)
- Safety evaluation of surovatamig: Frequency of dose limiting toxicities (DLTs).Time frame: Day 1 to end of the study (up to 52 weeks)
- Safety of surovatamig: Incidence of AEs/SAEs leading to discontinuation of surovatamigTime frame: Day 1 to end of the study (up to 52 weeks)
- Tolerability of surovatamig: Incidence of treatment-related vital signs abnormalitiesTime frame: Day 1 to end of the study (up to 52 weeks)
- Tolerability of surovatamig: Incidence of treatment-related clinical laboratory abnormalitiesTime frame: Day 1 to end of the study (up to 52 weeks)
- Tolerability of surovatamig: Number of participants with abnormal ECGTime frame: From baseline through Day 180.
Locations
35 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Withdrawn
Research Site
Fullerton, California · Recruiting
Research Site
Plantation, Florida · Not yet recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
Allen, Texas · Recruiting
Research Site
Mesquite, Texas · Recruiting
Research Site
Birtinya, Australia · Recruiting
Research Site
Clayton, Australia · Recruiting
Research Site
Edegem, Belgium · Recruiting
Research Site
Leuven, Belgium · Not yet recruiting
Research Site
Liège, Belgium · Recruiting
Research Site
Merksem (Antwerpen), Belgium · Recruiting
Research Site
Porto Alegre, Brazil · Recruiting
Research Site
Salvador, Brazil · Recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Nanjing, China · Recruiting
Research Site
Bonn, Germany · Recruiting
Research Site
Jena, Germany · Recruiting
Research Site
Mainz, Germany · Withdrawn
Research Site
München, Germany · Not yet recruiting
Research Site
Münster, Germany · Not yet recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Córdoba, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Kaohsiung City, Taiwan · Recruiting
Research Site
Taichung, Taiwan · Recruiting
Research Site
Taipei, Taiwan · Recruiting
Research Site
Taoyuan, Taiwan · Recruiting
Research Site
Kyiv, Ukraine · Recruiting
Research Site
Ternopil, Ukraine · Recruiting
Research Site
Vinnytsia, Ukraine · Recruiting
Research Site
London, United Kingdom · Not yet recruiting
Research Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.